US › Healthcare

Novavax Inc (NVAX)

US · Healthcare · Biotechnology

$7.66+3.37%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$139.5M
Revenue YoY
-79.1%
Net profit
$-9.5M
Profit YoY
-101.8%
EPS
$-0.06
EPS estimate
$-0.37
Net margin
-6.8%

EPS came in at -0.06 against a street estimate of -0.37 — a beat of 83.8%.

Key statistics

Market cap
$1.20B
Forward P/E
2.6
P/B
41.23
Book value
$-0.88
EPS (TTM)
$-0.56
52-week high
$11.97
52-week low
$6.20
50-day MA
$8.98
200-day MA
$8.47
Beta
2.43

Analyst view

Analysts rate Novavax Inc a buy (5 buy, 1 hold, 3 sell out of 9) with an average price target of $14.11.

Shareholding

Insiders
5.08%
Institutions
69.42%

Largest institutional holders

FundStake
Shah Capital Management9.03%
BlackRock Inc7.81%
State Street Corp5.46%
D. E. Shaw & Co LP4.69%
Vanguard Portfolio Management, LLC4.35%
Vanguard Capital Management, LLC4.34%
Sanofi4.18%
Bank of America Corp4.04%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Novavax Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.